16 assets in Astrocytic Tumor

Therapeutic assets addressing Astrocytic Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Astrocytic Tumor	Oliver Jonas	P2	BB (68)
Dabrafenib Astrocytic Tumor	Novartis Pharmaceuticals	P4	BB (65)
Trametinib Astrocytic Tumor	Novartis Pharmaceuticals	P4	BB (65)
Adriamycin Astrocytic Tumor	Oliver Jonas	P2	B (60)
Etoposide Astrocytic Tumor	Oliver Jonas	P2	B (60)
Apixaban Astrocytic Tumor	University of Vermont Medical Center	P2	CCC (53)
Olutasidenib Astrocytic Tumor	Rigel Pharmaceuticals	P2	CCC (53)
Disodium 4-((Tert-Butylimino)Methyl)Benzene-1,3-Disulfonate N-Oxide Astrocytic Tumor	Oblato, Inc.	P1/2	CCC (52)
Cyclophosphamide Astrocytic Tumor	Oliver Jonas	P1	CCC (48)
Ad5-yCD Astrocytic Tumor	Henry Ford Health System	P1	CC (43)
ad5-ycd/muttksr39rep-adp adenovirus Astrocytic Tumor	Henry Ford Health System	P1	CC (43)
c134 Astrocytic Tumor	James Markert, MD	P1	CC (43)
Eflornithine Astrocytic Tumor	Orbus Therapeutics, Inc.	P1	CC (43)
ft536 Astrocytic Tumor	Masonic Cancer Center, University of Minnesota	P1	CC (43)
G 207 Astrocytic Tumor	M.D. Anderson Cancer Center	P1	CC (43)
Rqnestin Astrocytic Tumor	Dana-Farber Cancer Institute	P1	CC (43)